My photo was used to illustrate this post
Photo by swanksalot (CC BY-SA 2.0) Successful efforts by patient advocacy groups to require new approval standards for a particular class of drugs have resulted, perhaps inadvertently, in a sharp reduction of available products and a spike in the cost of brand name drugs to a tune of $350 million per year, Gastroenterology & Endoscopy News contributor Monica J. Smith reports.
click here to keep reading :
Did Pharmaceutical Firms Exploit Pancreas Problems to Increase Profits? – Truthdig
automatically created via Delicious and IFTTT